MedTrace Logo

Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma

NCT07456605 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-06-12

No results posted yet for this study

Summary

The purpose of this study is to test the safety of in investigational drug called Liposomal curcumin (LipoCurc) and to find the highest dose that can be given without causing very severe side effects.

To do this participants are given LipoCurc and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then new participants will be given a higher dose of LipoCurc. Participants joining this study later on will get higher doses of LipoCurc than participants who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given.

Conditions

  • Multiple Myeloma Refractory
  • Multiple Myeloma in Relapse

Interventions

DRUG

Liposomal Curcumin (LipoCurc)

LipoCurc contains a substance called curcumin. Curcumin is a natural ingredient found in a plant called turmeric, which is a herb used in traditional Indian and Chinese medicine. Curcumin has been shown in the laboratory to have antioxidant (may help prevent damage to cells),anti-inflammatory (may help reduce swelling, redness, or pain), and anti-cancer (can kill multiple myeloma cells) properties. Curcumin supplements participants can buy at a drugstore as pills are not absorbed well by the body. This product has been developed so the body can absorb much more of it through an infusion into the veins.

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-27
Primary Completion
2028-03-02
Completion
2028-03-02

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07456605 on ClinicalTrials.gov